CADL (Candel Therapeutics) Non Operating Income: $-17.01 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CADL Candel Therapeutics Inc CADL
21 GF Score
Price $12.15
! 3 Warning Signs
View Full Analysis

What is Candel Therapeutics Non Operating Income?

Candel Therapeutics CADL +3.67% 21 Non Operating Income is $-17.01 Mil as of Jun. 2026. GuruFocus rates CADL with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Candel Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was $-12.28 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-17.01 Mil.

Candel Therapeutics Non Operating Income Related Terms

Candel Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Candel Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Candel Therapeutics Non Operating Income Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial -11.42 16.37 0.97 -20.80 8.20

Candel Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 1.15 -13.52 7.64 -12.28
CADL
21GF Score
Candel Therapeutics Inc CADL
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Candel Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-17.01 Mil mean?
Candel Therapeutics (CADL) has a Non Operating Income of $-17.01 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Candel Therapeutics and its competitors.
Is Candel Therapeutics' Non Operating Income too high?
Candel Therapeutics' current Non Operating Income is $-17.01 Mil. Overall, Candel Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' Non Operating Income compare to NGNE and CTMX?
Candel Therapeutics' Non Operating Income of $-17.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current Non Operating Income is $-17.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current Non Operating Income of $-17.01 Mil. The current Non Operating Income is $-17.01 Mil. Candel Therapeutics' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current Non Operating Income is $-17.01 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Candel Therapeutics Business Description

Address 117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
21GF Score

Get the complete analysis for CADL

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.15
Price